| Code | CSB-RA017647MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody B1655, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces and promoting their lysosomal degradation. By reducing LDLR availability, elevated PCSK9 levels lead to increased circulating LDL cholesterol, a major risk factor for atherosclerotic cardiovascular disease. Loss-of-function mutations in PCSK9 are associated with lower LDL cholesterol and reduced cardiovascular risk, while gain-of-function mutations cause familial hypercholesterolemia.
This biosimilar antibody provides researchers with a cost-effective tool for investigating PCSK9 biology and its therapeutic inhibition. It is suitable for studies examining PCSK9-LDLR interactions, lipid metabolism pathways, and cardiovascular disease mechanisms. The antibody enables exploration of PCSK9's role in cholesterol regulation and supports preclinical research into lipid-lowering therapeutic strategies.
There are currently no reviews for this product.